These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 12858128)

  • 1. The effects of LDL reduction and HDL augmentation on physiologic and inflammatory markers.
    Kuvin JT; Karas RH
    Curr Opin Cardiol; 2003 Jul; 18(4):295-300. PubMed ID: 12858128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients.
    Yadav R; Liu Y; Kwok S; Hama S; France M; Eatough R; Pemberton P; Schofield J; Siahmansur TJ; Malik R; Ammori BA; Issa B; Younis N; Donn R; Stevens A; Durrington P; Soran H
    J Am Heart Assoc; 2015 Sep; 4(9):e001508. PubMed ID: 26374297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HDL-C: role as a risk modifier.
    Barter P
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Niacin's role in the statin era.
    Brooks EL; Kuvin JT; Karas RH
    Expert Opin Pharmacother; 2010 Oct; 11(14):2291-300. PubMed ID: 20569085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treating high density lipoprotein cholesterol (HDL-C): quantity versus quality.
    Pirillo A; Norata GD; Catapano AL
    Curr Pharm Des; 2013; 19(21):3841-57. PubMed ID: 23286430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HMG-CoA reductase inhibition: anti-inflammatory effects beyond lipid lowering?
    März W; Wieland H
    Herz; 2000 Mar; 25(2):117-25. PubMed ID: 10829251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The role of the high-density lipoprotein (HDL) particle in atherogenesis and potential methods to increase HDL concentrations].
    Birjmohun RS; van der Steeg WA; Stroes ES; Kastelein JJ
    Ned Tijdschr Geneeskd; 2006 Oct; 150(41):2245-50. PubMed ID: 17076358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The facts behind niacin.
    Hochholzer W; Berg DD; Giugliano RP
    Ther Adv Cardiovasc Dis; 2011 Oct; 5(5):227-40. PubMed ID: 21893559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential role of HDL- and LDL-cholesterol modulation in atheromatous plaque development.
    Chapman MJ
    Curr Med Res Opin; 2005; 21 Suppl 6():S17-22. PubMed ID: 16138937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controversies on HDL: should it be a target biomarker in patients with lipid disorders?
    Nicholls SJ; Andrews J; Duong M
    Curr Vasc Pharmacol; 2014; 12(4):649-52. PubMed ID: 23627977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Raising low levels of high-density lipoprotein cholesterol is an important target of therapy.
    Boden WE; Pearson TA
    Am J Cardiol; 2000 Mar; 85(5):645-50, A10. PubMed ID: 11078282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy.
    Rosenson RS
    Am Heart J; 2006 Mar; 151(3):556-63. PubMed ID: 16504615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of low HDL-cholesterol levels in the reduction of cardiovascular risk].
    Stokić E; Marinkov J
    Med Pregl; 2007; 60(3-4):145-50. PubMed ID: 17853726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond LDL-C--the importance of raising HDL-C.
    Wierzbicki AS; Mikhailidis DP
    Curr Med Res Opin; 2002; 18(1):36-44. PubMed ID: 11999145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: Implications for coronary atheroma progression and cardiovascular events.
    Puri R; Nissen SE; Shao M; Kataoka Y; Uno K; Kapadia SR; Tuzcu EM; Nicholls SJ
    Eur J Prev Cardiol; 2016 Mar; 23(5):474-85. PubMed ID: 25691546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insights from recent meta-analysis: role of high-density lipoprotein cholesterol in reducing cardiovascular events and rates of atherosclerotic disease progression.
    Negi S; Ballantyne CM
    J Clin Lipidol; 2010; 4(5):365-70. PubMed ID: 21122680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.